RxDoctor Payments Data

Michael Malizia

Psychiatric/Mental Health · Johns Island, SCNPI 1508357534

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,429, more than ten times the $89 reported in 2023. Among psychiatric/mental health clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,353in general payments, 2019–2025

Across 331 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$741
  • Vanda Pharmaceuticals Inc.$680
  • E.r. Squibb & Sons, L.L.C.$521
  • Otsuka America Pharmaceutical, Inc.$490
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$457
  • Neurocrine Biosciences, Inc.$450
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$6,353100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,353 in reported general payments places this provider in the 90th percentile of 354 psychiatric/mental health providers in South Carolina.

See all psychiatric/mental health providers in South Carolina

Medicare billing

Part B allowed, 2024
$14,048
Medicare patients
22
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clozapine12$949
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine27$729
Duloxetine Hcl21$701
Quetiapine Fumarate17$550
Bupropion XlBupropion Hcl30$478
Lamotrigine18$229
Fluoxetine Hcl16$192
Trazodone Hcl21$157
Lorazepam30$151
Eszopiclone17$88
Clonazepam15$83
Propranolol Hcl14$78
Sertraline Hcl11$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$221$6111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 354 psychiatric/mental health providers in South Carolina.

Other psychiatric/mental health in Johns Island

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →